Neurology – Page 5

Impaired Sleep Homeostasis and Respiratory Instability: Identifying Novel Biomarkers for Sudden Unexpected Death in Epilepsy

By MedXY 12/23/2025

This case-control study identifies altered slow-wave activity progression and increased respiratory variability during NREM sleep as significant biomarkers for SUDEP risk, providing a potential framework for objective clinical screening and risk stratification in epilepsy patients.

Emergency Medicine Neurology news

Remote Expertise, Local Impact: Telemedicine Models Outperform Onboard Care in Mobile Stroke Units

By MedXY 12/23/2025

The MSU-TELEMED trial demonstrates that telemedicine models for Mobile Stroke Units are superior to onboard neurologist care. By dramatically improving physician resource utilization without compromising safety, telemedicine provides a more sustainable and scalable framework for prehospital stroke intervention.

Neurology news

Home-Based Gamma tACS Improves Cognitive Function and Daily Living in Alzheimer Disease: Results from a Randomized Clinical Trial

By MedXY 12/22/2025

A randomized clinical trial demonstrates that home-based gamma transcranial alternating current stimulation (tACS) over the precuneus safely improves cognitive outcomes and activities of daily living in patients with prodromal and mild Alzheimer disease, supported by neurophysiological evidence of brain engagement.

Neurology news Psychiatry

Scalable Solutions for Sleep: Converging Evidence from a Nationwide RCT and Meta-Analysis Validates Digital CBT-I

By MedXY 12/21/2025

This article analyzes a nationwide decentralized RCT and a systematic meta-analysis to evaluate the efficacy of digital Cognitive Behavioral Therapy for Insomnia (CBT-I), highlighting its role as a scalable, evidence-based first-line treatment for chronic insomnia disorder.

Neurology news Pediatrics

Precision Prognostics: Automated EEG Background Analysis and 2-Year Outcomes in Neonatal Hypoxic-Ischemic Encephalopathy

By MedXY 12/21/2025

This article explores how automated EEG background analysis via the Brain State of the Newborn (BSN) score provides objective, early-life prognostication for neonates with HIE, significantly improving the prediction of 2-year neurodevelopmental outcomes compared to clinical variables alone.

Neurology news

Azathioprine in Early Parkinson’s Disease: Trial Fails Primary Endpoint but Reveals Sex-Specific Immune Signals

By MedXY 12/19/2025

The AZA-PD phase 2 trial found that while azathioprine was well-tolerated in early Parkinson's disease, it did not significantly improve gait-axial scores. However, exploratory data suggests potential motor benefits in female patients and modulation of central immune biomarkers.

Neurology news

The LAST-long Trial: Monthly Coordination Fails to Prevent Functional Decline in Mild Stroke Patients

By MedXY 12/19/2025

The LAST-long randomized trial found that an 18-month coordinator-led multimodal intervention did not significantly prevent functional decline or dependency in patients with mild stroke compared to standard care, highlighting challenges in improving outcomes for high-functioning survivors in robust healthcare systems.

Critical Care Neurology news

Rising Hospital Mortality and Escalating Rates of Life-Sustaining Therapy Withdrawal in Critically Ill TBI Patients: A 15-Year Analysis

By MedXY 12/19/2025

A 15-year observational study of over 45,000 TBI patients reveals a significant increase in hospital mortality and a tripling of life-sustaining therapy withdrawal, alongside rising rates of hypoxaemia, raising urgent questions about ethical frameworks and neurocritical care management.

AI Neurology news

AI-Driven Imaging Decision Support Doubles Thrombectomy Rates in Real-World Stroke Care

By MedXY 12/19/2025

A large-scale prospective study across England's NHS reveals that AI imaging software significantly boosts endovascular thrombectomy rates for acute stroke patients. Implementation was associated with a 100% relative increase in treatment at evaluation sites, highlighting AI's potential to bridge gaps in emergency neurointerventional care.

Infectious Diseases Neurology news

The SEIZURE Score Faces Global Challenges: International Validation Highlights Geographic Disparities in Predicting Encephalitis Seizures

By MedXY 12/18/2025

An international evaluation of the SEIZURE score reveals limited global predictive power for acute seizures in encephalitis. While the tool performs well in Western Europe, particularly Portugal, its utility elsewhere is hampered by etiological diversity and diagnostic limitations.

Infectious Diseases Neurology news

High-Dose Oral Rifampin Did Not Improve Survival in Tuberculous Meningitis—HARVEST Trial Shows No Benefit and Possible Harm

By MedXY 12/18/2025

A multinational randomized trial found that adding high‑dose oral rifampin (total 35 mg/kg for 8 weeks) to standard therapy did not reduce 6‑month mortality in adults with tuberculous meningitis and was associated with more drug‑induced liver injury and earlier deaths in some patients.

Neurology news Oncology

Chemoendocrine Therapy Linked to Greater Cognitive Decline in Breast Cancer Patients, Regardless of Menopausal Status

By MedXY 12/17/2025

A secondary analysis of the RxPONDER trial finds chemoendocrine therapy causes more lasting cognitive impairment than endocrine therapy alone in both pre- and postmenopausal women.

Neurology news Psychiatry

Elevated Serotonin Release in Schizophrenia: New Insights Into Negative Symptom Pathophysiology

By MedXY 12/17/2025

A PET imaging study reveals increased frontal serotonin release in schizophrenia, particularly in deficit type, tied to worse negative symptoms.

Cardiology Neurology news

Combined Cardiorespiratory and Resistance Training After Stroke: Small Gains, Big Questions

By MedXY 12/17/2025

Evidence suggests combined aerobic and strength training post-stroke yields modest improvements in fitness and function but uncertain long-term benefits.

Neurology news

Do Behavioural, Self-Management, and Service Delivery Models Improve Outcomes in Adults with Epilepsy?

By MedXY 12/17/2025

A Cochrane review finds limited and low- to moderate-certainty evidence that behavioural, self-management, or service delivery interventions improve seizure control or quality of life in adults with epilepsy.

Diabetes & Endocrinology Neurology news

Omega-3 Fatty Acids Show Limited Benefits for Diabetic Peripheral Neuropathy

By MedXY 12/17/2025

Current evidence suggests minimal impact of omega-3 supplementation on neuropathy symptoms or quality of life in adults with diabetes.

Neurology news Pediatrics

Limited Evidence for Behavioural and Service Delivery Interventions in Childhood Epilepsy: Urgent Need for Robust Trials

By MedXY 12/16/2025

Current evidence for behavioural and service delivery interventions in childhood epilepsy is scarce and of low quality, highlighting an urgent need for rigorous, long-term trials.

Cardiology Neurology news

Low-Dose Colchicine Reduces Myocardial Infarction and Stroke Risk in Cardiovascular Disease Patients

By MedXY 12/16/2025

A large meta-analysis shows colchicine can lower MI and stroke risk without raising serious adverse events, but GI side effects remain a concern.

Neurology news Oncology

Acupuncture for Cancer-Related Insomnia: Limited, Low-Certainty Benefits Compared with Sham or No Treatment; Inferior to CBT‑I

By MedXY 12/16/2025

A 2025 Cochrane review (5 RCTs, 402 patients, mainly women with breast cancer) finds very low- to moderate-certainty evidence that acupuncture delivers small, uncertain sleep diary benefits versus sham or inactive controls and is probably less effective than CBT‑I for insomnia in people with cancer.

Neurology news

FDA Approves Inebilizumab (Uplizna) for Antibody-Positive Generalized Myasthenia Gravis: Interpreting the MINT Trial and Clinical Implications

By MedXY 12/15/2025

The FDA has approved inebilizumab-cdon (Uplizna) for adults with AChR- or MuSK-antibody positive generalized myasthenia gravis based on the phase 3 MINT trial showing a 1.9-point MG‑ADL improvement at 26 weeks versus placebo and sustained benefit in AChR+ patients through 52 weeks.